化合物Altiratinib T2054

Product Introduction
Bioactivity


英文名: Altiratinib

描述: Altiratinib (DCC-2701) 是一种多靶点激酶抑制剂，能够抑制 MET (IC50:2.7 nM)，TIE2 (IC50:8 nM)，VEGFR2 (IC50:9.2 nM)，FLT3 (IC50:9.3 nM)，Trk1 (IC50:0.85 nM)，Trk2 (IC50:4.6 nM) 和 Trk3 (IC50:0.83 nM)。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 45 mg/mL (88.15 mM)


关键字: Cluster of differentiation antigen 135 | c-Met/HGFR | Trk Receptor | Inhibitor | CD135 | inhibit | Altiratinib | FLT3 | Vascular endothelial growth factor receptor | Tropomyosin related kinase receptor | DCC 2701 | VEGFR | DCC2701 | Fms like tyrosine kinase 3

相关产品: VEGFR-2/c-Met-IN-1 | Tanshinone IIA | BMS-605541 | AZD4547 | Chloropyramine hydrochloride | GW806742X | SAR131675 | BMS-794833 | VEGFR2/HDAC1-IN-1 | TG 100572

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Fluorochemical Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Kinase Inhibitor Library | Anti-Colorectal Cancer Compound Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library

化合物Altiratinib T2054信息由TargetMol中国为您提供，如您想了解更多关于化合物Altiratinib T2054报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途